α4 Integrin blockade in inflammatory bowel disease
- 1 November 2003
- journal article
- review article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 62 (suppl 2) , ii70-ii72
- https://doi.org/10.1136/ard.62.suppl_2.ii70
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Natalizumab for Active Crohn's DiseaseNew England Journal of Medicine, 2003
- A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha‐4 integrinAlimentary Pharmacology & Therapeutics, 2002
- A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active crohn's diseaseGastroenterology, 2001
- Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's diseaseGastroenterology, 2001
- An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC)Gastroenterology, 2000
- Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel diseaseThe Lancet, 1998
- A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's diseaseGastroenterology, 1998
- Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7Gastroenterology, 1996
- Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody.Journal of Clinical Investigation, 1993